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A B S T R A C T
GATA4-6 transcription factors regulate numerous aspects of development and homeosta-
sis in multiple tissues of mesodermal and endodermal origin. In the heart, the best studied
of these factors, GATA4, has multiple distinct roles in cardiac specification, differentiation,
morphogenesis, hypertrophy and survival.To improve understanding of how GATA4 achieves
its numerous roles in the heart, here we have focused on the carboxy-terminal domain and
the residues required for interaction with cofactors FOG2 and Tbx5. We present evidence
that the carboxy terminal region composed of amino acids 362–400 is essential for medi-
ating cardiogenesis in Xenopus pluripotent explants and embryos. In contrast, the same region
is not required for endoderm-inducing activity of GATA4. Further evidence is presented that
the carboxy terminal cardiogenic region of GATA4 does not operate as a generic transcrip-
tional activator. Potential mechanism of action of the carboxy terminal end of GATA4 is
provided by the results showing physical and functional interaction with CDK4, including
the enhancement of cardiogenic activity of GATA4 by CDK4. These results establish CDK4
as a GATA4 partner in cardiogenesis. The interactions of GATA4 with its other well de-
scribed cofactors Tbx5 and FOG2 are known to be involved in heart morphogenesis, but their
requirement for cardiac differentiation is unknown.We report that the mutations that disrupt
interactions of GATA4 with Tbx5 and FOG2, G295S and V217G, respectively, do not impair
cardiogenic activity of GATA4. These findings add support to the view that distinct roles of
GATA4 in the heart are mediated by different determinants of the protein. Finally, we show
that the rat GATA4 likely induces cardiogenesis cell autonomously or directly as it does not
require activity of endodermal transcription factor Sox17, a GATA4 target gene that induces
cardiogenesis non-cell autonomously.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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1. Introduction
GATA family of Zn finger transcription factors constitutes
6 multifunctional regulators of numerous aspects of verte-
brate embryonic development and adult physiology. GATA4-6
factors are preferentially involved in development and func-
tion ofmesodermal (heart, vasculature, gonads) and endodermal
organs (lungs, liver, gut).
Perhaps the best studied among the GATA4-6 factors is
GATA4, and in particular its roles in cardiovascular develop-
ment and homeostasis. Molecular genetic analyses in the
mouse, zebrafish and Xenopus, as well as information from pa-
tients, have revealed specific roles of GATA4 in virtually all stages
and all aspects of heart development and postnatal function
– specification, differentiation, growth, morphogenesis, regen-
eration, cell survival and hypertrophy (Aries et al., 2004; Charron
et al., 2001; Garg et al., 2003; Haworth et al., 2008; Holtzinger
and Evans, 2005; Kikuchi et al., 2010; Liang et al., 2001a, 2001b;
Pu et al., 2004; Watt et al., 2004).
Together with chromatin remodelling factor BAF60c and
Tbx5, GATA4 can induce ectopic cardiogenesis in the mouse
embryo (Takeuchi and Bruneau, 2009), whereas in the Xenopus
embryo and in P19 cells it is sufficient on its own (Grepin et al.,
1997; Latinkic et al., 2003). GATA4 is an essential com-
ponent of various cocktails of transcription factors that have
been shown to reprogram non-cardiac somatic cells into
cardiomyocytes (Fu et al., 2013; Ieda et al., 2010; Nam et al.,
2013; Qian et al., 2012).
In the adult mammalian heart, GATA4 mediates
cardiomyocyte hypertrophy in a process that is thought to re-
semble aspects of cardiac development, as suggested by
activation of a set of cardiomyocyte gene products that are nor-
mally expressed in developing, immature cells in cells
undergoing hypertrophy (Frey and Olson, 2003; Molkentin and
Dorn, 2001).
However, the roles of GATA4 in development versus hyper-
trophy are clearly distinct, as shown by the finding that Ser
105 of GATA4, whose phosphorylation by MAPK is required for
hypertrophy, is not involved in mediating cardiogenic activi-
ty of GATA4 and is not required for heart development
(Gallagher et al., 2012; van Berlo et al., 2011).
GATA4 is thought to achieve its roles through a multitude
of mechanisms, including regulated expression, participa-
tion in various multiprotein complexes and extensive post-
translational modifications (Zhou et al., 2012). However, the roles
that these modifications play in mediating various activities
of GATA4 in vivo are just beginning to emerge. One example
is the role of MAPK-mediated phosphorylation of S105 in me-
diating cardiac hypertrophy (van Berlo et al., 2011). Another one
is provided by a recent finding that Cyclin D2 is a cofactor of
GATA4 in cardiogenesis (Yamak et al., 2014). The physical and
functional interactions between GATA4 and Cyclin D2 depend
on phosphorylation of Ser 160 of GATA4, which can be medi-
ated in vitro by CDK4 (Yamak et al., 2014).
The physiological roles for interactions of transcription factor
partners of GATA4 have been studied for Tbx5 and FOG2. The
GATA4-FOG2 interaction was investigated using homozygous
mice carrying an interaction-disruptingV217G mutation; these
animals die in mid-gestation due to the absence of coronary
blood vessels and suffer defective morphogenesis of the valves
and major blood vessels (Crispino et al., 2001). This pheno-
type is distinct from the null GATA4 and myocardium-specific
knockouts, but is similar to the FOG2 null phenotype (Tevosian
et al., 2000), establishing a specific role for GATA4-FOG2 inter-
action in the development of coronary blood vessels. Another
example of a physiologically important partnering of GATA4
was provided by the finding that the G296S mutation affects
the interaction between GATA4 and Tbx5 and it leads to con-
genital heart disease in patients (Garg et al., 2003), while in
homozygous mutant mice it causes mid-gestation lethality
(Misra et al., 2012).
To improve our knowledge of the mechanisms through
which GATA4 acts in heart development, we focused on the
roles played by the C-terminus and the residues important for
the interaction with Tbx5 and FOG2 in GATA4-induced cardiac
differentiation.
2. Material and methods
2.1. Xenopus embryos and explants
This work was approved by Cardiff University’s Ethical
Review Committee and was carried out under a license from
the UK Home Office. Xenopus embryos were obtained and cul-
tured as previously described (Sive et al., 2000). Explants (stage
8.5) were dissected and cultured in 75% Normal Amphibian
Media (NAM); supplemented with gentamycin sulphate (50 µg/
ml; Sigma). All rat GATA4 plasmids were linearised with Asp718
(Roche). The wt and 201–440 rGATA4 plasmids have been pre-
viously described (Gallagher et al., 2012).Xenopus tropicalis CDK4
full-length coding sequence in pCS107 (TGas100g18; Gilchrist
et al., 2004) and Cyclin D2 (Yamak et al., 2014) were used as a
template to make capped RNA. Sox17β and Sox17β::EnR tran-
scription templates were generated as described (Hudson et al.,
1997). CappedmRNAwas synthesised using mMessageMachine
kit (Ambion/ABI), and RNA was subsequently purified on
Sephadex G50 columns (ProbeQuant; GE Healthcare). RNA
samples were injected into embryos using an IM 300 Micro-
injector (Narishige Scientific). For animal cap explant
experiments, 400 pg of GATA4 RNA was co-injected with a mix
of rhodamine-dextran (20 mg/ml) and dextran-biotin (25 mg/
ml) lineage tracers (Invitrogen) (Latinkic et al., 2003) in 10 nl/
embryo at 1–2 cell-stage.All GATA4 variants were tested at least
twice and most constructs, including non-cardiogenic 1–361,
were tested more than four times. For ectopic cardiac tissue
formation assay, 2 nl (80 pg) of RNA was injected in one an-
terior dorsal blastomere at 8–16 cell stage. These ectodermal
precursors are away from the developing heart and are per-
missive for ectopic cardiac tissue induction by GATA4 (Gallagher
et al., 2012). In this assay, 10–15% of embryos injected with car-
diogenic GATA4 variants typically show ectopic expression; total
number of embryos examined was n = 40–60 from two or three
independent experiments. Given relatively low penetrance of
ectopic cardiogenesis in this assay, but unequivocal nature of
induction of ectopic cardiac expression, the results are qual-
itative and conclusive when n ≥ 40. 200 pg of Sox17β or
Sox17β::EnR capped mRNA was injected per embryo (Fig. 6).
Cardiac actin-GFP transgenic line and its use in detecting
32 mechan i sm s o f d e v e l o pm ent 1 3 4 ( 2 0 1 4 ) 3 1 – 4 1
cardiogenesis in animal pole explants were described (Latinkic
et al., 2002; Latinkic et al., 2003).
2.2. Cell cultures and transfections
National Institutes of Health NIH3T3 cells lines were main-
tained and transfected as previously described (Yamak et al.,
2014). The CDK inhibitor RO506220 was obtained from Roche
(Burgess et al., 2006; Yamak et al., 2014). All plasmids used were
previously described (Yamak et al., 2014).
2.3. Recombinant DNA
For gain of function studies in Xenopus, rat GATA4 se-
quences together with an N-terminal HA tag were generated
by high fidelity PCR using Phusion polymerase (NEB) and were
cloned in pCS2 vector via BamHI/EcoRI sites. Primer se-
quences are available upon request.Two copies of the minimal
transcriptional activation domain of VP16 (amino acids
413–454) together with the flexible hinge region of the lambda
repressor (Brickman et al., 2000) were fused to rGATA4
1–361 and 201–440 at the C-terminal end by overlap PCR.
Expected coding regions generated by PCR were confirmed
by sequencing.
2.4. Reverse Transcription-PCR (RT-PCR)
Total RNA was isolated from samples using the
acid guanidinium thiocyanate-phenol-chloroform method
(Chomczynski and Sacchi, 1987). Approx. 20 animal caps were
used per sample, and cDNA was synthesised using MMLV-
Reverse Transcriptase and random hexamers (both Invitrogen)
according to the manufacturer’s instructions. Primer se-
quences and PCR cycling conditions were as described (Samuel
and Latinkic, 2009). PCR was performed with GoTaq enzyme
(Promega).
2.5. Whole-mount in situ hybridisation (WMISH)
WMISH was carried out as described (Sive et al., 2000), using
the digoxigenin (Roche)-labelled antisense riboprobe for
myl7 (also known as MLC2; Chambers et al., 1994). Colour was
developed using BM Purple (Roche).
2.6. Protein analyses
Immunohistochemistry on blastula-stage Xenopus embryos
was performed as described (Sive et al., 2000), using rat mono-
clonal α-HA-HRP (1:2,500; Roche) and DAB substrate (Sigma).
Images were taken on Leica MZ16 stereomicroscope with
DFC300FX Leica camera and were processed with Adobe
Photoshop software. Western blotting of Xenopus protein ex-
tracts was performed as described (8). Total cell extracts were
prepared from 1–2 µl lysis buffer/animal cap. 10 µl samples were
resolved by polyacrylamide gel electrophoresis and trans-
ferred to PVDF membrane (Millipore) and blotted by standard
techniques. Antibodies used were rat monoclonal α-HA-HRP
(1:2,500; Roche) and as a loading control α-Erk (1:2,500; Santa-
Cruz). Secondary antibody was goat α-rabbit HRP (Chemicon;
1:5,000). Detection was achieved using chemiluminescent
detection kit (Thermo/Pierce). For in vitro pull-down assay, the
recombinant GST-GATA4 proteins production and pull down
assays were performed as described previously (Yamak et al.,
2014). For luciferase assays Xenopus embryos were injected with
indicated RNAs together with 30 pg each of 2XGATALuc (Grepin
et al., 1994) and TK-RL (Promega). Dual Luciferase Assays
(Promega) were carried out as recommended by the manufac-
turer on extracts from approximately 20 animal caps per
sample, collected 3 hours after excision at st. 9.
2.7. Molecular modelling
Modelling was carried out using SWISSMODEL (Arnold et al.,
2006). The figure was created with PyMOL software (http://
www.pymol.org).
3. Results
3.1. Carboxy-terminal domain of GATA4 is required for
cardiogenesis
We have recently demonstrated that a region within the
N-terminal domain of GATA4, aa 129–153, is required for
cardiogenesis in pluripotent animal cap explants from Xenopus
embryos (Gallagher et al., 2012), but the roles of the C-terminal
region of GATA4 were not examined.To investigate the role of
the C-terminal region in mediating cardiogenic activity of
GATA4, we first tested a deletion that removes the final 78
amino acids, rGATA4 1–361.The mutant protein was efficient-
ly produced in embryos and was properly localised to the nuclei,
but it was incapable of inducing cardiomyocyte differentia-
tion, both in animal cap explants and in embryos (Fig. 1B). In
contrast, the 1–361 mutant has retained the capacity to induce
markers of endothelium and blood (Fig. 1).
Further evidence that the 1–361 mutant was not simply in-
active, despite being non-cardiogenic, came from extended
marker expression analysis: the endogenous gata4 was found
to be induced at st. 10 (gastrulation) and a marker of endo-
derm, a2m (endodermin) was expressed at st. 34 (Fig. 1E,F).
These results suggest that the removal of carboxy-terminal 78
amino-acids selectively affects cardiogenic activity of the GATA4
protein. Amino acid sequence of the C-terminus of GATA4 that
is required for cardiogenesis is poorly conserved with a related
cardiogenic factor GATA5 and offers no obvious clues about its
mechanism of action (Fig. 1A).
3.2. Carboxy-terminal domain of GATA4 is required for
interaction with CDK4
To investigate the mechanisms through which the carboxy
terminal domain of GATA4 might operate, using candidate ap-
proach we focused on CDK4. In a recent study we have shown
that CDK4 activity is required for GATA4-driven transcription
(Yamak et al., 2014). One way in which CDK4 could affect GATA4
activity is through enabling synergism between GATA4 and
Cyclin D2, as physical and functional interactions of GATA4 with
Cyclin D2 depend on S160, a residue that can be phosphory-
lated by CDK4 in vitro (Yamak et al., 2014). To determine which
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region of GATA4 is required for interaction with CDK4, we per-
formed in vitro pull down assays of CDK4 with GST-N- or
C-terminal GATA4 proteins. Fig. 2A shows that CDK4 only binds
the C-terminal region of GATA4. As stated above, our previ-
ous results have indicated that CDK4 phosphorylates N-terminal
domain of GATA4 and that amino acid S160 is required for phos-
phorylation (Yamak et al., 2014). Taken together, these data
suggest that CDK4 binds to and phosphorylates distinct
domains of GATA4.
We next wished to determine if the C-terminal domain of
GATA4 is required for transcriptional synergy between GATA4
and CDK4 (Yamak et al., 2014). To do this, we co-transfected
wt GATA4 or C-terminal-deletion mutant 1–361 with CDK4 and
a GATA site-dependent reporter. As shown in Fig. 2B, full length
(wt) GATA4 but not the C-terminal mutant synergises with CDK4
in transcriptional activation. The requirement of GATA4
C-terminal domain for interaction with CDK4 was confirmed
by testing the effect of CDK4 inhibitor on C-terminal mutant.
Consistent with our previous data (Yamak et al., 2014), treat-
ment with CDK4 inhibitor reduces GATA4 activation of its target
promoter dramatically. This effect requires the C-terminal
domain of GATA4 (Fig. 2C).
To test whether transcriptional synergy between GATA4
and CDK4 observed in cell culture might be of relevance
Fig. 1 – Carboxy-terminal domain (362–440) of GATA4 is required for cardiogenesis. (A) Schematic representation of GATA4
structure showing transcriptional activation domains (TAD), Zn fingers (Zn), nuclear localisation signal (nls) and the
position of mutations tested in this study. Right – sequence of the C-terminal region of GATA4 (rat, NP_653331; Xenopus
NP_001085355) and GATA5 (rat NP_001019487; Xenopus NP_001081962), showing poor conservation in these cardiogenic
factors. (B) Deletion of C-terminal 78 amino acids abolishes cardiogenic activity of GATA4. Animal caps injected with wt or
1–361 mutant rGATA4 were tested for expression of cardiomyocyte-specific genes myl7 and myh6 (synonyms: Myosin Light
Chain 2 and Myosin Heavy Chain α, respectively) at st.34 and for levels of GATA4 protein at st. 10 (lower panel). Note that
the effect of this deletion is negligible on endothelial marker aplnr (apelin receptor; synonym- msr) and is less pronounced
on hba3 (haemoglobin alpha 3; synonym- αglobin), a blood marker. odc1- loading control (expression of ornithine
decarboxylase 1). (C) Nuclear localisation of 1–361 rGATA4 was determined by immunohistochemistry at st. 7–8. (D) Lack of
activity of 1–361 in vivo. Embryos injected with 1–361 rGATA4 at 8–16 cell-stage in anterior ectodermal precursors were
analysed for myl7 expression by whole mount hybridisation. myl7 expression was only observed in the heart (h) in all
embryos examined (n = 50, from 2 independent experiments). In contrast, cardiogenic GATA4 versions readily induce
ectopic myl7 expression (Figs 3 and 5). (E) Non-cardiogenic 1–361 GATA4 mutant retains gene expression-inducing activity
in animal cap explants. At st. 10 the mutant 1–361 induces endogenous gata4 and (F) at st. 34 pan-endodermal marker
alpha-2 macroglobulin (a2m; synonym – endodermin) is induced (as well as by N-terminal deletions 153–440 and 201–440
non-cardiogenic GATA4 (Gallagher et al., 2012)).
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to cardiogenic activity of GATA4, we examined the ability of
GATA4 to induce cardiac differentiation in animal cap ex-
plants in the absence or presence of exogenous CDK4 or
CyclinD2, an established cardiogenic cofactor of GATA4 (Yamak
et al., 2014). CDK4 alone had no effect on cardiogenesis, but
it enhanced the cardiogenic activity of GATA4 similar to
CyclinD2 (Fig. 2D), suggesting that transcriptional synergy
between GATA4 and CDK4 might have a role in cardiogenesis.
To refine the C-terminal region of GATA4 that is required
for cardiogenesis, we tested smaller deletions, 1–425 and 1–400.
Both deletions did not abolish cardiogenic activity of GATA4
and had not altered protein stability or nuclear localisation
(Fig. 3) thus mapping the C-terminal cardiogenic region to aa
362–400. We have additionally tested point mutations that
abolish protein kinase C (PKC) phosphorylation sites (S419A and
S420A), as PKC was shown to enhance activity of GATA4 in cell
culture (Wang et al., 2005). These mutations (mPKC) had no
effect on cardiogenic activity of GATA4, suggesting that PKC
modification is not involved in regulation of GATA4-mediated
cardiogenesis (Fig. 3).
Fig. 2 – CDK4 interacts with C-terminal GATA4 in vitro and enhances cardiogenic activity of GATA4 (A) In vitro translated
35S radio-labelled CDK4 protein was incubated with GST-N-terminal GATA4, GST-C-terminal GATA4 or GST proteins on
glutathione sepharose beads. The bound proteins were resolved by SDS/PAGE and revealed by autoradiography. Note that
CDK4 binds C-terminal GATA4 (1st lane). The experiment is one representative of two. (B) Fold synergy of wild type GATA4
(1–440) or C-terminal deletion (1–361) with CDK4 on GATA-dependent promoter. The C-terminal region is required for
synergy. 10 ng of GATA4 and 100 ng of CDK4 expression vectors were used. The experiment was performed twice.
* p < 0.005 of GATA4 1–440/CDK4 fold synergy vs GATA4 1–440 using Student’s t test. (C) NIH3T3 cells were transiently
transfected with GATA-luc and increasing doses of the indicated GATA4 expression vector (5, 25, 50 and 100 ng) with our
without treatment with 3 µM CDK4 inhibitor. The cells were treated the following day after transfection and kept for 18 hrs.
Note that 1–361 GATA4 activation is not inhibited by CDK4. Experiment was performed twice. # p < 0.001 of GATA4 1–440
with CDK4 inhibitor vs. GATA4 1–440 using two-way ANOVA. (D) CDK4 enhances cardiogenic activity of GATA4. Animal cap
explants injected with indicated capped mRNAs (400 and 100 pg/embryo of CDK4 and CyclinD2 (CycD2), respectively;
300 pg/embryo of rGATA4 (suboptimal dose)) were analysed for expression of cardiomyocyte marker myl7 at st. 34.
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3.3. Partial rescue of cardiogenic activity of inactive rGATA4
mutants by a heterologous activation domain
The non-cardiogenic mutant rGATA4 aa 201–440 (Gallagher
et al., 2012) lacks the known activation domains in the
N-terminus of the protein (Morrisey et al., 1997), and similar-
ly the 1–361 mutant lacks the region required for transcriptional
activation (Zhou et al., 2012). These observations raise a pos-
sibility that these mutants may be non-cardiogenic simply
because of compromised transcriptional activity. An addition-
al question raised by these results is whether the deleted
transactivation domains provide ‘generic’ activity or are perhaps
specifically required for the cardiogenic role of the protein. To
address these questions we supplied two copies of the minimal
transactivation domain from strong transactivator VP16
(Brickman et al., 2000) to the 1–361 and 201–440 mutants. The
resulting fusion proteins behave as more potent transactivators
of a GATA site-driven synthetic reporter gene than the wt
rGATA4 (Fig. 4A). In contrast, they are much weaker cardio-
genic inducers compared to the wt rGATA4 (Fig. 4B). These
results suggest that the N- and C-terminal domains of rGATA4
do not simply have a generic transactivation role but addi-
tionally provide a degree of specificity to cardiogenic activity
of the protein. This conclusion was supported by examining
the expression of markers of other cell fates induced by GATA4:
the 201–440 and 1–361 VP fusions were indistinguishable from
the wt rGATA4 in their ability to induce the expression of en-
dothelial and blood markers (Fig. 4C).
3.4. GATA4-induced cardiogenesis does not require residues
important for interaction with FOG2 and Tbx5
GATA4 has multiple roles in development and in post-
embryonic life. It is thought that these roles are at least in part
mediated through interaction of GATA4 with various cofac-
tors. One of these factors, FOG2, interacts with the N-terminal
Zn finger of GATA4 to mediate development of coronary blood
vessels, andV217 is essential for this interaction (Crispino et al.,
2001). A mutation of a residue in the vicinity of V217, E215D,
has been implicated in cardiac roles of GATA4 as it has been
detected in some patients withTetralogy of Fallot (Nemer et al.,
2006). As shown in Fig. 5, V217G and E215D mutations did not
affect the ability of rGATA4 to induce cardiac differentiation
in animal cap explants.
The C-terminal Zn finger of GATA4 interacts with numer-
ous partners, including T box transcription factor Tbx5, an
important regulator of heart development. The importance of
the interaction of GATA4 and Tbx5 for heart development has
been suggested by human genetics studies which have
reported patients with congenital heart disease carrying the
G296S mutation in the GATA4 protein (Garg et al., 2003). The
G296S mutation was found to affect the interaction of GATA4
with Tbx5, in addition to leading to reduced DNA binding and
transactivation activities (Garg et al., 2003).
We next tested the effect of G295S mutation on the car-
diogenic activity of rGATA4 (Gly at position 295 in the rat GATA4
is equivalent to Gly 296 in the human protein). The mutant
Fig. 3 – Deletion of 15 or 40 C-terminal amino acids does not block cardiogenic activity of GATA4. (A) Expression of myh6
and odc1 in st. 34 animal caps expressing wt, 1–400, 1–425 and 1–425 mPKC (S419A; S420A) versions of rGATA4. Western
blot analysis (lower panel) of protein levels at st. 10. (B) Nuclear localisation of 1–400, 1–425 and 1–425 rGATA4. (C) Embryos
injected in anterior ectodermal blastomeres at 8–16 cell stage with 1–400, 1–425 and 1–425 were analysed for myl7
expression at st. 34. myl7 was detected in the heart (h) and in ectopic locations (arrows) of representative embryos (out of
40, 4–7 embryos showed ectopic cardiac expression).
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protein was found to have wt-like cardiogenic activity (Fig. 5).
In addition, the G295S mutation did not affect the ability of
GATA4 to induce markers of endothelium, blood and liver
(Fig. 5). This finding was unexpected, in light of reported
compromised DNA binding of the G296S mutant (Garg et al.,
2003), and we wished to examine it in more detail.
We have established that the rat GATA4 G295S affects
DNA binding of the protein (data not shown), in agreement with
previous results. To better understand the structural basis for
properties of the mutant protein, we considered several
possible explanations. First, the glycine residue might adopt
a main chain conformation that is inaccessible to amino acids
with side chains. Hence, the G295S mutation might enforce
changes in main chain conformation and thus destabilise the
structure. Second, the serine 295 might directly interfere with
DNA binding, due to a steric clash with the DNA. Finally, G295S
mutation might indirectly influence the DNA binding proper-
ties of GATA4.
In order to distinguish between these possibilities, we first
modelled the complex of the second zinc finger of rat GATA4
with target DNA, using the solution structure of DNA-bound
GATA1 as the template (pdb-accession 3GAT, Omichinski et al.,
1993).We considered this as a valid approach, because GATA1
and GATA4 share the specificity for the GATA sequence in target
DNA and are highly similar in the region around conserved
G295. We then manually introduced a serine residue in the
position of glycine 295. We note that in the template struc-
ture and in the model, Gly adopts a helical main chain
conformation that is also accessible to serine. Hence, a
destabilisation of the GATA4 (and also GATA1) structures due
to Ramachandran angle constraints for serine (or other amino
acids with side chains) is unlikely. Also, the model shows that
the serine is too far away to clash with the DNA directly, elimi-
nating the second possible explanation of the G295 effect on
DNA binding. However, we found that the introduced serine
295 in the GATA4 model (and also the GATA1 template)
packs too tightly against the side chain of arginine R282, a
predicted DNA-contacting side chain (Fig. 5E). The clash is
relatively mild (distance from the Cβ of S295 to the arginine
side chain ≈ 3.2 Å), but independent of the choice of serine
rotamer, since it also involves the Cβ, which has a Cβ posi-
tion uniquely defined by themain chain conformation.The R282
has hydrogen bonds with the guanidino group of its side chain
with the Hoogsteen edge of a guanine of the GATA binding site.
Hence, the model is consistent with an indirect effect of the
G295S mutation on DNA binding through an effect of the
mutation on the conformation of R282. We note the limita-
tions of this explanation for the reduced DNA binding of
GATA4 G295S that the clash is only mild and is within the
range of coordinate errors for models based on similar
templates.
3.5. Cell autonomous induction of cardiogenesis by rGATA4
We have shown that Xenopus GATA4 induces endoderm in
animal cap explants from Xenopus embryos (Gallagher et al.,
2012; Latinkic et al., 2003) and that it induces cardiogenesis both
cell autonomously and non-cell autonomously (Latinkic et al.,
2003), suggesting that non-cell autonomous cardiogenesis is
mediated by cardiogenic endoderm.As our model for structure–
function mapping of rGATA4 depends on exclusive cell
autonomous or direct mode of cardiogenesis, we investi-
gated this issue in more detail.
GATA4 induces early endoderm transcription factor, Sox17
(Gallagher et al., 2012; Latinkic et al., 2003).We have tested the
ability of Sox17-expressing animal cap explants to induce
cardiogenesis when conjugated to Sox17- or un-injected animal
caps. Cardiogenesis was only induced by Sox17-expressing
animal caps in naïve, uninjected animal caps (Fig. 6). In both
types of conjugates (i.e., Sox17 + Sox17 and Sox17 + AC) Sox17
induced endoderm (Fig. 6E).These result demonstrate that Sox17
only induces cardiogenesis indirectly, non-cell autonomously.
In our cardiogenesis assays for rGATA4, the mRNA is injected
uniformly,making non cell-autonomousmode of cardiogenesis,
like the one demonstrated for Sox17, unlikely. To directly test
if Sox17 is involved in rGATA4-mediated cardiogenesis, we in-
terfered with Sox17 function by using dominant-negative
construct Sox17::EnR (Hudson et al., 1997; Latinkic et al., 2003).
Expression of Sox17::EnR caused severely compromised en-
doderm development, confirming its activity (data not shown).
We found that interfering with Sox17 function enhances
rGATA4-mediated cardiogenesis (Fig. 6F), showing not only that
Sox17 is not required for cardiogenic activity of rGATA4, but
Fig. 4 – Non-cardiogenic GATA4 mutants lacking N- or
C-terminus can be partially rescued by a heterologous
transcriptional activator. (A) 1–361 and 201–440 VP fusions
are stronger transcriptional activators than the wt rGATA4.
Embryos were injected at 1- or 2-cell stage with a firefly
luciferase reporter under the control of two GATA sites,
Renilla luciferase plasmid driven by the thymidine kinase
(TK) promoter and indicated mRNAs. Control-DNA alone
sample. Animal caps were excised at st. 8.5 and collected
for analysis 3 hours later. GATA-luc activity represents
relative fold activation (firefly luciferase activity normalised
by Renilla luciferase activity, with control (no mRNA)
sample set at 1). In three separate experiments 201–
440 + VP and 1–361 + VP were found to be considerably
more active than the wt rGATA4, with variable fold
differences but consistent trend of 201–440 + VP and
1–361 + VP showing 5–10 times greater activity than the wt
rGATA4. (B) VP16 minimal activation domain (VP) weakly
rescues cardiogenic activity of 1–361 and 201–440, as
assessed by expression of myl7 and myh6. (C) In contrast,
the ability of 1–361 and 201–440 VP fusions to induce the
expression of endothelial marker aplnr and a blood marker
hba3 is comparable to the wt rGATA4.
37mechan i sm s o f d e v e l o pm ent 1 3 4 ( 2 0 1 4 ) 3 1 – 4 1
also that it might have an inhibitory cell-autonomous effect.
Finally, we have used the enhancement of GATA4-mediated
cardiogenesis by Sox17::EnR to confirm that inactive rGATA4
mutants, 1–361 and 201–440, do not have residual level of
activity (data not shown).
4. Discussion
4.1. Cell autonomous cardiogenic activity of mammalian
GATA4
In addition to cardiovascular cell types (cardiomy-
ocytes, endothelium, smooth muscle) GATA4 induces early
endoderm and liver specification in pluripotent cells from
Xenopus embryos (Latinkic et al., 2003). As anterior endoderm
produces cardiogenic signals, it was important to investigate
the mode of action of GATA4 in cardiogenesis assay in more
detail. Early endoderm determinant Sox17 was shown
to be required for cardiogenesis in mouse ES cells cell
non-autonomously (Liu et al., 2007). We have previously
shown that GATA4 induces Sox17 in animal cap explants
from Xenopus embryos (Latinkic et al., 2003), and here we have
extended this finding by showing that in our assay Sox17
induces cardiac tissue cell non-autonomously, similarly as in
ES cells. However, the activity of Sox17 is not required for
cardiogenesis mediated by the rat GATA4, suggesting that the
model we use likely represents cell-autonomous and direct
action of GATA4.
Fig. 5 – Cardiogenic activity of GATA4 does not require residues which are essential for interaction with FOG2 or Tbx5.
(A) E215D, V217G and G295S mutations do not affect cardiogenesis induced by GATA4 in animal pole explants, as assessed
by expression of myh6 at st. 34. Bottom panel – Western blot analysis of rGATA4 variants in animal caps collected at st. 10.
(B) Nuclear localisation of E215, V217G and G295S GATA4 mutants. (C) Ectopic myl7 expression (arrows) induced by
indicated mutants in representative embryos (out of 50, 4–10 embryos showed ectopic myl7 expression). (D) In addition to
being able to efficiently induce cardiac differentiation markers myh6 and myl7, V217G and G295S mutants are
indistinguishable from the wt rGATA4 in their ability to induce liver (nr1h5; synonym-for1), endothelium (aplnr) and blood
(hba3) markers. (E) Model of the C-terminal Zn finger of GATA4 with G295S mutation. The key side chains, Ser295 and
Arg282, are indicated. The model shows the clash that would occur with the mutation in the absence of backbone or side
chain adaptations to resolve it.
38 mechan i sm s o f d e v e l o pm ent 1 3 4 ( 2 0 1 4 ) 3 1 – 4 1
4.2. C-terminal domain of GATA4 is required for cardiogenic
activity and for interaction with CDK4
We have previously shown that the aa 129–153 region of the
rat GATA4 is required for cardiogenesis in animal cap ex-
plants from Xenopus embryos (Gallagher et al., 2012).This region
is also required for interaction of GATA4 with chromatin
remodeller BAF60c (Gallagher et al., 2012). In this work we have
extended structure–function mapping of GATA4 to the
C-terminus. Our results demonstrate that the region com-
posed of aa 362–400 is required for cardiogenesis, as the 1–361
deletion mutant was inactive, whereas the 1–400 mutant was
indistinguishable from the wt GATA4.
An insight into the potential mechanism through which the
C-terminal domain of GATA4 might act came from an exten-
sion of our recent study which has shown that CyclinD2 is a
cofactor of GATA4 in cardiogenesis (Yamak et al., 2014). Cyclin
D2 binds to the N-terminal region of GATA4, and a residue crit-
ical for CyclinD2–GATA4 synergy, S160, was shown to be
phosphorylated by CDK4 (Yamak et al., 2014). However, it
was not known if CDK4 directly interacts with GATA4. In this
study we show that the C-terminal region of GATA4 interacts
with CDK4 in vitro, and that the region aa 362–440 is required
for their transcriptional synergy (Fig. 2). In addition, we have
shown that CDK4 can enhance cardiogenic activity of GATA4
(Fig. 2).These findings provide a potential mechanism through
which C-terminal region of GATA4 could be involved in
cardiogenesis.
Both cardiogenic regions described within GATA4 (362–
400 (this work) and 129–152 (Gallagher et al., 2012)) are located
within the domains associated with transcriptional activity
(Zhou et al., 2012). Here we have shown that a strong heter-
ologous activation domain from VP16 can weakly rescue
cardiogenic activity missing in the N- and C-terminal dele-
tions (1–201 and 361–440) of GATA4. The evidence suggesting
that transcriptional activation domains are involved in
mediating cardiogenic activity of GATA4 is perhaps not sur-
prising. More tellingly, even though fusion of VP16-derived
activation domain turns non-cardiogenic GATA4 mutants into
strong transactivators, the cardiogenic activity of 1–361-VP16
and 201–440-VP16 is weak. This result suggests that the N-
and C-terminal regions of GATA4 operate as transcriptional
activators with preference for cardiac tissue. Other findings
support the view that non-cardiogenic mutants of GATA4 1–361
and 201–440 are not simply transcriptionally inactive: both
mutants can induce endoderm in animal cap explants
(Fig. 1; Gallagher et al., 2012), suggesting that cardiac- and
endoderm-inducing determinants are separable. These find-
ings provide the foundation for investigation of themechanisms
regulating the activity of cardiogenic domains and how they
differ from the mechanisms mediating endoderm-inducing
activities.
Fig. 6 – Non-cell autonomous induction of cardiogenesis in animal cap explants by Sox17. Animal caps derived from
cardiac actin–GFP (CA-GFP) embryos injected with 200 pg of Sox17 mRNA or uninjected (AC) were conjugated and cultured
until st. 34. Different animal caps in each conjugate were distinguished by the presence of rhodamine-dextran in one of
them. (A–D) Bright field images of representative examples of indicated types of explants. (A’–D’) Corresponding red and
green fluorescence images (merged), showing contribution of rhodamine-dextran injected animal caps and the presence or
absence of striated muscles (CA-GFP; Latinkic et al., 2003). CA-GFP activity was only detected in naïve, uninjected part of
Sox17+AC conjugates, indicating non-cell autonomous cardiac induction. The number of conjugates showing the
represented phenotype and the total number of conjugates are shown in the lower right corner (A–D). (E) Activity of Sox17
is shown by induction of endoderm marker a2m in st. 10 animal cap explants. (F) Inhibition of Sox17 function by
Sox17::EnR does not block cardiogenesis by rGATA4. rGATA4 (400 pg/embryo) and Sox17::EnR (200 pg per embryo) were
uniformly injected at 1- or 2-cell stage and RT-PCR was performed at st. 34 for myl7 and odc1 loading control.
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4.3. GATA4-Tbx5 and GATA4-FOG2 interactions are not
required for GATA4-induced cardiogenesis
G296 of the human GATA4 (G295 in rodent GATA4) is known
to be important for efficient DNA binding and for association
with Tbx5 (Garg et al., 2003). In particular, mutation G296S in
the human GATA4 has been associated with congenital heart
defects, highlighting the importance of intact GATA4 for heart
development (Garg et al., 2003).
In the current study we have provided a potential struc-
tural basis for lower DNA binding affinity of the G295S mutant.
Our modelling suggests that the DNA-contacting arginine
residue R282 might be destabilised by the bulkier serine side
chain at position 295 instead of glycine. Despite the effect of
the G295S mutation on DNA binding of GATA4, we found the
mutant to be indistinguishable from the wt GATA4 in its in-
duction of cardiomyocyte, endothelial, blood and liver markers
in animal cap explants. Our results indicate that the interac-
tion of GATA4 withTbx5 is not required for cell fate specification
by GATA4, and also suggest that lower affinity for DNA in vitro
of the mutant does not affect its cardiogenic activity. These
results suggest that the intrinsically lower DNA binding ca-
pacity of the G295S GATA4 mutant can be compensated in vivo
in the chromatin context. We do not believe that in our gain
of function assay mass action leads to such a compensation,
as the level of overexpression is modest (400 pg/embryo) and
is just above the suboptimal dose (≈300 pg/embryo).
A recent study has investigated the role of G295 in mouse
development by creating GATA4 G295S knock-in homozy-
gous animals (Misra et al., 2012). The observed effects – an
embryonic lethality phenotype that was milder than the null
embryo phenotype – argue that G295S causes partial loss of
function. Some targets of GATA4, namely endodermal and a
set of cardiac markers, were not affected by the G295S muta-
tion. Instead, the most striking effect seen in G295S mutants
was a defect in myocardial proliferation, which led to the
development of hypoplastic myocardium and which likely
caused lethality.
These results, showing that early heart development in the
mouse embryo is largely unaffected by the G295S mutation,
are in good agreement with our findings.The difference is that
we have not identified a process (or processes) that require G295
in our work using Xenopus embryos.This is likely because early
heart development in the frog Xenopus is independent of pro-
liferation (Movassagh and Philpott, 2008), in contrast to the
mouse heart, suggesting that amajor role of G295 within GATA4,
and by extension of GATA4-Tbx5 interaction, is specifically in
regulation of cardiomyocyte proliferation.
It is surprising that a major functional and likely structur-
al defect caused by the G295S mutation has no effect on the
ability of GATA4 to induce cardiac and other cell types in
Xenopus animal cap explants, and similarly, apparently has no
effect on a subset of target genes in the mouse embryo (Misra
et al., 2012). Finding out how different targets of GATA4 dis-
tinguish between the wt and G295S will improve our knowledge
of the mechanism of action of this important regulator of gene
expression.
Another well described cofactor of GATA4 is FOG2.Work in
transgenic mice has shown that a null mutation of FOG2 and
a point mutation of GATA4 that specifically abrogates its
interaction with FOG2 (V217G), in homozygous animals create
very similar phenotypes (Crispino et al., 2001; Tevosian et al.,
2000). These are characterised by the defective development
of coronary vessels, resulting in lethality at E12.5 and dem-
onstrating that interaction of GATA4 with FOG2 is important
for normal heart development (Crispino et al., 2001). Our results
have shown that theV217G mutation has no effect on cell fate
specification activity of GATA4 in Xenopus animal cap
explants. Similarly, the E215D mutation, found in patients with
Tetralogy of Fallot (Nemer et al., 2006), had no effect on
cardiogenic activity of GATA4.
4.4. Conclusion – separable and specific determinants are
required for various roles of GATA4 in the heart
Here we have assigned a role to C-terminal region of GATA4
(aa 362–400) in cardiogenesis, and we have provided evi-
dence that the basis for this role likely involves transcriptional
activation in cardiac precursors.A potential mechanism through
which the C-terminal region of GATA4 promotes cardiogenesis
is provided by the findings that CDK4 interacts with it, thereby
promoting its transcriptional and cardiogenic activity.
Our results in the present study have shown that the de-
terminants of activity of GATA4 in heart morphogenesis and
growth, G295, V217 and E215, are not necessary for its cardio-
genic activity. We have previously shown that S105, which is
required for interaction with Serum Response Factor and is a
key mediator of cardiomyocyte hypertrophy, is similarly not
required for cardiogenic activity of GATA4 (Gallagher et al., 2012).
Taken together, these findings argue that distinct mecha-
nisms are involved in mediating the roles of GATA4 during
different stages of heart development and postnatal
homeostasis, and offer an opportunity to investigate howmul-
tifunctional transcription factors execute their distinct roles
in vivo.
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